These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19792969)

  • 21. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
    Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
    Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
    Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone and prostate cancer: what are the risks for middle-aged men?
    Morgentaler A
    Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between prostate cancer and serum testosterone levels.
    Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
    Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
    Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
    Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
    J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum androgens: associations with prostate cancer risk and hair patterning.
    Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
    J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgens and prostate cancer risk: a prospective study.
    Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
    Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
    Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
    Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
    Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
    Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone in prostate cancer: the Bethesda consensus.
    Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
    BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
    Crawford ED
    Urology; 2009 May; 73(5 Suppl):S4-10. PubMed ID: 19375626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Cavalleri S; Artibani W
    Urol Int; 2013; 91(1):55-61. PubMed ID: 23751412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question.
    Reis LO
    Endocr Relat Cancer; 2012 Jun; 19(3):R93-8. PubMed ID: 22399012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.